These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 1948918)

  • 21. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hypertension, microalbuminuria and insulin resistance in diabetes mellitus].
    Bretzel RG
    Wien Klin Wochenschr; 1994; 106(24):774-92. PubMed ID: 7846897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular risk factors in the metabolic syndrome: impact of insulin resistance on lipids, hypertension, and the development of diabetes and cardiac events.
    Zarich SW
    Rev Cardiovasc Med; 2005; 6(4):194-205. PubMed ID: 16379015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Period prevalence of abnormal glucose tolerance and cardiovascular risk factors among obese children attending an obesity centre in Italy.
    Invitti C; Gilardini L; Pontiggia B; Morabito F; Mazzilli G; Viberti G
    Nutr Metab Cardiovasc Dis; 2006 May; 16(4):256-62. PubMed ID: 16679217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension: a new perspective in therapy and metabolic effect. Part I.
    Medina Ruiz A
    Bol Asoc Med P R; 1991 Sep; 83(9):399-401. PubMed ID: 1807274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between hypertension and subtle and overt abnormalities of carbohydrate metabolism.
    Sowers JR
    J Am Soc Nephrol; 1990 Sep; 1(3 Suppl 1):S39-47. PubMed ID: 16989076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].
    Lièvre M
    Rev Prat; 2001 Oct; 51(16):1793-9. PubMed ID: 11795124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic syndrome X: a review.
    Timar O; Sestier F; Levy E
    Can J Cardiol; 2000 Jun; 16(6):779-89. PubMed ID: 10863169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic risk factors and markers of cardiovascular and renal damage in overweight subjects.
    Bigazzi R; Bianchi S; Batini V; Guzzo D; Campese VM
    Am J Hypertens; 2006 Apr; 19(4):426-31. PubMed ID: 16580581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hypercholesterolemia as cardiovascular risk in hypertensive patients. Therapeutic implications: efficiency of statins].
    Borghi C; Veronesi M
    Recenti Prog Med; 2003 Oct; 94(10):421-6. PubMed ID: 14619187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
    Nakamura K; Yamagishi S; Inoue H
    Med Hypotheses; 2005; 65(1):155-7. PubMed ID: 15893134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of metabolic syndrome.
    Wagh A; Stone NJ
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of abdominal obesity in pathogenesis of insulin resistance syndrome].
    Almazov VA; Blagosklonnaia IaV; Shliakhto EV; Krasil'nikova EI
    Ter Arkh; 1999; 71(10):18-22. PubMed ID: 10612167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypertension and associated cardiovascular risk factors in Kelantan.
    Mafauzy M; Mokhtar N; Wan Mohamad WB
    Med J Malaysia; 2003 Oct; 58(4):556-64. PubMed ID: 15190632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Physical activity and the metabolic syndrome].
    Westheim A; Os I; Hjermann I
    Tidsskr Nor Laegeforen; 1993 Feb; 113(6):723-4. PubMed ID: 8465338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians - the Chennai Urban Rural Epidemiology Study (CURES-38).
    Mohan V; Sandeep S; Deepa M; Gokulakrishnan K; Datta M; Deepa R
    Diabetes Obes Metab; 2007 May; 9(3):337-43. PubMed ID: 17391160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetes and hypertension.
    Mahler RJ
    Horm Metab Res; 1990 Dec; 22(12):599-607. PubMed ID: 2076856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.